KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer.

Raza Khan, Niamh Coleman

Ther Adv Med Oncol 16 17588359241249627

PMID38765713
PMCIDPMC11102705
DOI10.1177/17588359241249627
发表日期2024-05-20
摘要

摘要

Small-cell lung cancer (SCLC) is a biologically aggressive subtype of lung cancer, a lethal disease characterized by rapid tumor growth, early relapse, a strong tendency for early widespread metastasis, and high genomic instability, making it a formidable foe in modern oncology practice. While the management of non-SCLC has been revolutionized in the era of immunotherapy, progress in SCLC has been more muted. Recent randomized phase III clinical trials have combined programmed death ligand-1 inhibitors to a chemotherapy backbone and demonstrated improved survival; however, the absolute benefit observed is short months. There is an undeniable urgent need for better responses, better agents, novel therapeutic approaches, and more rational, biomarker-driven clinical trials in SCLC. In this review, we discuss the rationale and current understanding of the biology of SCLC in the modern era of immunotherapy, discuss recent advances in front-line immunotherapeutic approaches that have changed clinical practice globally, provide an overview of some of the challenges and limitations that have staggered immune checkpoint blockade in SCLC, and explore some of the novel immunotherapeutic approaches currently being investigated.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。